Technical Analysis for PHAR - Pharming Group N.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 9.35 | 0.21% | 0.02 |
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.21% | |
| Doji - Bullish? | Reversal | 0.21% | |
| Lower Bollinger Band Walk | Weakness | 0.21% | |
| New 52 Week Low | Weakness | 0.21% | |
| Stochastic Reached Oversold | Weakness | 0.21% | |
| Below Lower BB | Weakness | 0.21% | |
| Gapped Down | Weakness | 0.21% | |
| Oversold Stochastic | Weakness | 0.21% | |
| Volume Surge | Other | -8.06% | |
| Doji - Bullish? | Reversal | -8.06% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 1 hour ago |
| 1.5x Volume Pace | about 1 hour ago |
| 3x Volume Pace | about 1 hour ago |
| 5x Volume Pace | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
Pharming Group N.V. Description
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Pharmaceutical Biology Drug Discovery Angioedema Complement System Hereditary Angioedema Biopharmaceutical Products Acute Kidney Injury Complement Deficiency Pharming C1 Inhibitor Haemophilia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.71 |
| 52 Week Low | 9.27 |
| Average Volume | 2,884 |
| 200-Day Moving Average | 11.80 |
| 50-Day Moving Average | 11.18 |
| 20-Day Moving Average | 10.69 |
| 10-Day Moving Average | 10.40 |
| Average True Range | 0.51 |
| RSI (14) | 35.90 |
| ADX | 16.05 |
| +DI | 21.96 |
| -DI | 36.11 |
| Chandelier Exit (Long, 3 ATRs) | 10.26 |
| Chandelier Exit (Short, 3 ATRs) | 10.81 |
| Upper Bollinger Bands | 11.65 |
| Lower Bollinger Band | 9.73 |
| Percent B (%b) | -0.21 |
| BandWidth | 17.94 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.25 |
| MACD Histogram | -0.0889 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.98 | ||||
| Resistance 3 (R3) | 10.03 | 9.86 | 9.87 | ||
| Resistance 2 (R2) | 9.86 | 9.70 | 9.84 | 9.83 | |
| Resistance 1 (R1) | 9.60 | 9.60 | 9.73 | 9.55 | 9.80 |
| Pivot Point | 9.43 | 9.43 | 9.50 | 9.41 | 9.43 |
| Support 1 (S1) | 9.17 | 9.27 | 9.30 | 9.12 | 8.86 |
| Support 2 (S2) | 9.00 | 9.17 | 8.98 | 8.83 | |
| Support 3 (S3) | 8.74 | 9.00 | 8.79 | ||
| Support 4 (S4) | 8.69 |
